Ewelina Kiernozek

Dr. Ewelina Kiernozek


Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 May 2017 in Archivum Immunologiae et Therapiae Experimentalis
Verified
Journal Article
Open access
PDF file
KBKatarzyna Bocian
Katarzyna Bocian
EKEwelina Kiernozek
Ewelina Kiernozek
JDJoanna Domagała-Kulawik
Joanna Domagała-Kulawik
GKGrażyna Korczak-Kowalska
Grażyna Korczak-Kowalska
ASAnna Stelmaszczyk-Emmel
Anna Stelmaszczyk-Emmel
NDNadzieja Drela
Nadzieja Drela
Immunosuppressive activity of regulatory T and B cells is critical to limit autoimmunity, excessive inflammation, and pathological immune response to conventional antigens or allergens. Both types of regulatory cells are intensively investigated, however, their development and mechanisms of action are still not completely understood. Both T and B regulatory cells represent highly differentiated populations in terms of phenotypes and origin, however, they use similar mechanisms of action. The most investigated CD4+CD25+ regulatory T cells are characterized by the expression of Foxp3+ transcription factor, which is not sufficient to maintain their lineage stability and suppressive function. Currently, it is considered that specific epigenetic changes are critical for defining regulatory T cell stability in the context of their suppressive function. It is not yet known if similar epigenetic regulation determines development, lineage stability, and function of regulatory B cells. Phenotype diversity, confirmed or hypothetical developmental pathways, multiple mechanisms of action, and role of epigenetic changes in these processes are the subject of this review.

Verified
Journal Article
Open access
PDF file
JNJustyna Niderla-Bielińska
Justyna Niderla-Bielińska
AŚAneta Ścieżyńska
Aneta Ścieżyńska
AMAneta Moskalik
Aneta Moskalik
EJEwa A. Jankowska-Steifer
Ewa A. Jankowska-Steifer
KBKrzysztof Bartkowiak
Krzysztof Bartkowiak
ARAnna Ratajska
Anna Ratajska
Cardiac macrophages are known from various activities, therefore we presume that microRNAs (miRNAs) produced or released by macrophages in cardiac tissue have impact on myocardial remodeling in individuals with metabolic syndrome (MetS). We aim to assess the cardiac macrophage miRNA profile by selecting those miRNA molecules that potentially exhibit regulatory functions in MetS-related cardiac remodeling. Cardiac tissue macrophages from control and db/db mice (an animal model of MetS) were counted and sorted with flow cytometry, which yielded two populations: CD45+CD11b+CD64+Ly6Chi and CD45+CD11b+CD64+Ly6Clow. Total RNA was then isolated, and miRNA expression profiles were evaluated with Next Generation Sequencing. We successfully sequenced 1400 miRNAs in both macrophage populations: CD45+CD11b+CD64+Ly6Chi and CD45+CD11b+CD64+Ly6Clow. Among the 1400 miRNAs, about 150 showed different expression levels in control and db/db mice and between these two subpopulations. At least 15 miRNAs are possibly associated with MetS pathology in cardiac tissue due to direct or indirect regulation of the expression of miRNAs for proteins involved in angiogenesis, fibrosis, or inflammation. In this paper, for the first time we describe the miRNA transcription profile in two distinct macrophage populations in MetS-affected cardiac tissue. Although the results are preliminary, the presented data provide a foundation for further studies on intercellular cross-talk/molecular mechanism(s) involved in the regulation of MetS-related cardiac remodeling.

28 September 2022 in Foods
Verified
Journal Article
Open access
PDF file
EKEwelina Kiernozek
Ewelina Kiernozek
PMPiotr Maslak
Piotr Maslak
EKEwa Kozlowska
Ewa Kozlowska
IJIngeborga Jarzyna
Ingeborga Jarzyna
Dominika Średnicka-ToberDominika Średnicka-Tober
Dominika Średnicka-Tober
Maria RembiałkowskaMaria Rembiałkowska
Maria Rembiałkowska
For several decades, people have been searching for natural substances of plant origin that, when introduced into the diet, could strengthen immunity, have anticancer properties, and support conventional therapy. The development of agriculture with the implementation of various plant cultivation systems, apart from the economic aspect, results in the search for such cultivation conditions that would contribute to obtaining the most beneficial product for health. Therefore, the aim of our research is as follows: (a) to compare the antiproliferative activity and the ability to induce apoptosis of HT-29 cells by extracts from blueberry fruits deriving from different types of cultivation systems (conventional, organic, and biodynamic); (b) to examine whether the interaction of extracts with anticancer drugs used in the treatment of colorectal cancer is influenced by the type of cultivation, and (c) to investigate whether extracts obtained from fruits from subsequent years of cultivation retain the same biological activity. The results of our study are promising but inconclusive. A statistically significant difference occurred in only one of the two years of the study. The greatest inhibition of proliferation is observed for biodynamic cultivation compared to organic cultivation, while the highest levels of apoptosis and necrosis of HT-29 cells are induced by blueberry fruit extracts obtained from organic cultivation. The complementary effect of the extracts on the inhibition of HT-29 cell proliferation by anticancer drugs (5-FU and Erbitux) is not demonstrated. The induction of apoptosis by 5-FU is not enhanced by blueberry extracts, in contrast to necrosis. The level of apoptosis and necrosis induced by Erbitux is potentiated, but no dependence on crop type is shown. Blueberry fruit extracts from two consecutive years of cultivation did not maintain the same activity. A plausible reason for the variability in the composition and biological activity of fruit extracts obtained from two years of cultivation is the varying environmental conditions.

Verified
Journal Article
Open access
PDF file
MNMariola Napiórkowska
Mariola Napiórkowska
PKPratheeba Kumaravel
Pratheeba Kumaravel
Mithulya Amboo MahentheranMithulya Amboo Mahentheran
Mithulya Amboo Mahentheran
EKEwelina Kiernozek
Ewelina Kiernozek
EGEmilia Grosicka-Maciąg
Emilia Grosicka-Maciąg
A set of nine derivatives, including five brominated compounds, was synthesized and the structures of these novel compounds were confirmed using 1H and 13C NMR as well as ESI MS spectra. These compounds were tested on four different cancer cell lines, chronic myelogenous leukemia (K562), prostate cancer (PC3), colon cancer (SW620), human kidney cancer (Caki 1), and on healthy human keratocytes (HaCaT). MTT results reveal that two newly developed derivatives (6 and 8) exhibit selective action towards K562 cells and no toxic effect in HaCat cells. The biological activity of these two most promising compounds was evaluated by trypan blue assay, reactive oxygen species generation, and IL-6 secretion. To investigate the proapoptotic activity of selected compounds, the two following types of tests were performed: Annexin V Apoptosis Detection Kit I and Caspase-Glo 3/7 assay. The studies of the mechanism showed that both compounds have pro-oxidative effects and increase reactive oxygen species in cancer cells, especially at 12 h incubation. Through the Caspase-Glo 3/7 assay, the proapoptotic properties of both compounds were confirmed. The Annexin V-FITC test revealed that compounds 6 and 8 induce apoptosis in K562 cells. Both compounds inhibit the release of proinflammatory interleukin 6 (IL-6) in K562 cells. Additionally, all compounds were screened for their antibacterial activities using standard and clinical strains. Within the studied group, compound 7 showed moderate activity towards Gram-positive strains in antimicrobial studies, with MIC values ranging from 16 to 64 µg/mL.

1 September 2014 in Journal of Neuroimmunology
Verified
Journal Article
Closed access
EKEwelina Kiernozek
Ewelina Kiernozek
AKAnna Kowalik
Anna Kowalik
MMMagdalena Markowska
Magdalena Markowska
EKEwa Kozlowska
Ewa Kozlowska
NDNadzieja Drela
Nadzieja Drela

1 January 2019 in Journal of Trace Elements in Medicine and Biology
Verified
Journal Article
Closed access
EGEmilia Grosicka-Maciąg
Emilia Grosicka-Maciąg
DKDagmara Kurpios-Piec
Dagmara Kurpios-Piec
KWKatarzyna Woźniak
Katarzyna Woźniak
CKCezary Kowalewski
Cezary Kowalewski
MSMaria Szumiło
Maria Szumiło
IRIwonna Rahden-Staroń
Iwonna Rahden-Staroń